Microcurrent Stimulation Therapy for Intermediate to Advanced Nonexudative Age-related Macular Degeneration

Not Applicable

Recruiting

• Conditions: Age-Related Macular Degeneration; Age-related Macular Degeneration (ARMD); Intermediate AMD; Geographic Atrophy Secondary to Age-related Macular Degeneration

• Registration Number: NCT06662162
• Lead Sponsor: i-Lumen Scientific AUS PTY LTD

Brief Summary

The goal of this clinical trial is to characterize the safety and effectiveness of the i-Lumen AMD transpalpebral microcurrent device and therapy in patients with intermediate to advanced nonexudative AMD.

Participants will:

* Undergo an initial loading regimen, followed by 7 maintenance over the course of 11 months.

* Participants will return monthly through Month 14 (3 months post-last treatment) for evaluation and monitoring.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2024-10-25
• Study First Submitted QC: 2024-10-25
• Study First Posted: 2024-10-28
• Status Verified: 2025-05
• Last Update Submitted: 2025-05-06
• Study Start: 2025-05-07
• Last Update Posted: 2025-05-09
• Primary Completion: 2027-03-31
• Study Completion: 2029-12-31

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 100

Inclusion Criteria

• Presence of at least one large druse >125 microns in diameter due to AMD.
• BCVA letter score of 35 to 70 letters (inclusive) (Snellen equivalent 6/12 to 6/60 [20/40 to 20/200])

Key

Exclusion Criteria

• Any implanted electrical device(s) including deep brain stimulator, hearing or visual implants (i.e., cochlear implant, auditory brainstem implant, retinal prostheses), and/or cardiac defibrillator/pacemaker.
• Implanted metallic device within 20 cm of the Treatment electrode (study eye(s)) and/or the grounding electrode (base of the hairline on the back of the neck).
• Uncontrolled diabetes, defined as glycated haemoglobin (HbA1c) >10% (13.3 mmol/L).
• Current tobacco or tobacco-related product use or history within the past 5 years of heavy smoking (defined as, on average, more than half a pack of cigarettes per day).
• Known severe allergy to fluorescein dye.
• Medical diagnosis of severe dry eye defined as requiring either artificial tears more than six (6) times a day or prescription drops (i.e., Restasis, Xiidra, or Cequa).
• History of seizure disorders, chronic migraines and/or cluster headaches.
• History and/or evidence of diabetic retinopathy in either eye as assessed by CF, fundus fluorescein angiography (FA), and OCT, to be confirmed by the Central Reading Centre.
• Other conditions which pre-dispose to chorioretinal atrophy such as inherited retinal dystrophy (i.e., Stargardt's disease, Best's disease, pattern dystrophy, central areolar choroidal dystrophy, etc.).
• History and/or evidence of exudative AMD in the study eye as assessed by CF, FA (or OCT-A ), and OCT, to be confirmed by Central Reading Centre.
• GA involving the foveal centre, as assessed by the Central Reading Centre using AF and OCT.
• History of intravitreal injections for GA (e.g., Syfovre or Izervay).
• Treatment with photobiomodulation (PBM) therapy or short pulse laser within 12 months prior to screening.
• Glaucoma requiring ≥3 medications and/or drops per day, or history of trabeculectomy.
• History of any kind of intraocular surgery, excluding cataract surgery performed ≥3 months from Screening.
• History of yttrium aluminium garnet (YAG) laser posterior capsulotomy <1 month from Screening.
• Visually significant cataracts and/or visually significant posterior capsular opacification.
• History of amblyopia.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Primary Outcome Measures

Name	Time	Method
Mean Change BCVA from Baseline	Month 3	Mean change in per-eye (treated study eye \[unilateral\] or treated primary study eye \[bilateral\]) from Baseline in distance BCVA letter score on the ETDRS VA chart, active vs sham.

Secondary Outcome Measures

Name	Time	Method
Portion of per-eye Responders	Month 3	1. Difference in proportion of per-eye (treated study eye \[unilateral\] or treated primary study eye \[bilateral\]) gaining ≥10 letters from Baseline in distance BCVA ETDRS, active vs sham.
Mean Change BCVA from Baseline	Month 6	Mean change in per-eye (treated study eye \[unilateral\] or treated primary study eye \[bilateral\]) from Baseline in distance BCVA letter score on the ETDRS VA chart, active vs sham.

Trial Locations

Locations (4)

Adelaide Eye & Retina Centre; 🇦🇺 Adelaide, Victoria, Australia

Cerulea; 🇦🇺 East Melbourne, Victoria, Australia

Auckland Eye Limited; 🇳🇿 Remuera, Auckland, New Zealand

Southern Eye Specialist; 🇳🇿 Christchurch, New Zealand